Cargando…

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir

Detalles Bibliográficos
Autores principales:	Overton, T, Aberg, JA, Gupta, S, Ryan, R, Baugh, B, De La Rosa, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113080/ http://dx.doi.org/10.1186/1758-2652-13-S4-P74

Ejemplares similares

Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial
por: Overton, Edgar Turner, et al.
Publicado: (2016)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States
por: Brogan, Anita J., et al.
Publicado: (2018)

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy
por: Tsoukas, Christos, et al.
Publicado: (2013)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
por: Sension, M, et al.
Publicado: (2010)

Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
por: Mishra, Tulsidas, et al.
Publicado: (2014)

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
por: Robertson, Kevin, et al.
Publicado: (2018)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
por: Squires, Kathleen E, et al.
Publicado: (2017)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy
por: Gisslén, Magnus, et al.
Publicado: (2012)

Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir
por: Garvey, LJ, et al.
Publicado: (2010)

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
por: Colbers, Angela, et al.
Publicado: (2015)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
por: Smith, Kimberly Y, et al.
Publicado: (2008)

A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial
por: Ulbricht, K.U, et al.
Publicado: (2011)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
por: DeJesus, E, et al.
Publicado: (2010)

The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir
por: Wohl, DA, et al.
Publicado: (2015)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Atazanavir/ritonavir: QTc prolongation following off-label treatment: case report
Publicado: (2021)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
por: Arathoon, Eduardo, et al.
Publicado: (2017)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily
por: Zorrilla, CD, et al.
Publicado: (2014)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
por: Kort, Jens J, et al.
Publicado: (2011)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
por: Smith, Christiana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1eehrf20k2gq7mid98slc10a23